/lL to 138 3 10 3 /lL after plateletpheresis, but no individual was at risk for hemorrhage. Pooled platelet lysate had minimal cellular residue and contained growth factor concentrations at 6.1 ng/mL for transforming growth factor-b1, at 3.5 ng/mL for platelet-derived growth factor-BB, and at 13.8 ng/mL for vascular endothelial growth factor-A.
CONCLUSION: Plateletpheresis using commercially available apheresis equipment is a feasible option for collecting platelet concentrate from equine donors. The lysate generated from the apheresis product contains growth factors and has potential to be used as a fetal bovine serum substitute for cell culture.
P latelets are the principal source of growth factors, attachment factors, and enzymes found in serum. Platelet products, such as platelet-rich plasma, are extensively studied and used as therapeutics for healing wounds, soft tissues injuries, and a variety of musculoskeletal injuries in both human and veterinary patients. 1, 2 In addition, platelet-derived preparations have shown promise to replace fetal bovine serum (FBS) as a source of growth factors and vital nutrients in cell culture. [3] [4] [5] [6] [7] [8] The use of FBS as a media supplement is currently the gold standard in eukaryotic and stem cell culture. 9, 10 However, there is growing interest in finding suitable alternatives to FBS, because it is an ill-defined mixture of culture components and is ethically controversial in terms of the harvest and collection of FBS from bovine fetuses. 11 In addition, it contains endotoxins (lipopolysaccharide) and xenogenic antigens, which may alter the characteristics of mesenchymal stem cells (MSCs) developed for cell tranplantation. [12] [13] [14] Moreover, cells previously exposed to FBS may become carriers and serve as a potential route of transmission of animal pathogens. 10, 15, 16 This is especially critical when MSCs are used for clinical purposes. Therefore, it is important to develop expansion media for MSCs that contain recombinant growth supplements or that are sourced in a speciesspecific manner. Platelet lysate (PL) is an acellular serum substitute obtained after the lysis of platelet concentrates and is composed of growth and chemotactic factors that promote cell proliferation and recruitment. 3, 17, 18 PL has been used as an alternative to FBS for the expansion of stem cells in a variety of experimental and clinical cell transplantation studies. 3, 6, 19 For example, studies in human medicine have demonstrated that MSCs expanded in culture in the presence of PL maintain their differentiation potential and immunophenotypical profile. 7, 8 In contrast, there are no detailed functionality studies in veterinary medicine investigating a similar use of PL. Methods of collecting platelets for the production of PL include whole blood collection to obtain platelet-rich plasma or buffy coat-poor platelet concentrates and plateletpheresis. 3 The most commonly employed method to produce PL in human medicine begins with plateletpheresis, which has also been proven to be feasible and safe in dogs. [20] [21] [22] [23] [24] Apheresis equipment uses centrifugal technology to separate whole blood into its components, collecting platelets (plateletpheresis) and returning the uncollected components to the donor. Unlike whole blood collection, apheresis is a technique that does not deprive the donor of blood components, other than platelets, and thus is a potentially safer and more effective method of platelet collection. Currently, platelets are harvested from horses by collecting and processing whole blood on an as-needed basis. In fact, there are no specific protocols and no data regarding the feasibility of collecting high volumes of platelet concentrate from standing and awake horses using apheresis equipment. In this study, our goals were: 1) to safely obtain equine platelet concentrate using commercially available apheresis equipment, and 2) to manufacture equine PL and test its use as an alternative to FBS as a culture media supplement for the in vitro expansion of marrow-derived MSCs. We hypothesized that the process of collection would be conducted safely and without altering the hematologic, biochemical, and physical examination parameters of the donor horses.
MATERIALS AND METHODS

Equine platelet donors
In this study, six female horses belonging to the University of Georgia (UGA) were recruited for plateletpheresis. Horses were from mixed breeds with a mean age of 13 6 6 years and a mean weight of 513 6 64 kg. All donors were considered healthy based on history, preliminary blood work, and physical examination. The horses were transported to the UGA research facility before plateletpheresis for monitoring and acclimation. The study protocol (A2015 02-023-Y2-A2) was approved by the UGA Institutional Animal Care and Use Committee.
Plateletpheresis procedure
Plateletpheresis was performed according to the manufacturer's instructions (COBE Spectra Essentials Guide and Platelet Collection Guide, 2005; Gambro BCT) using a dual-needle, leukoreduction collection procedure (COBE Spectra Dual-Needle Extended Life Platelet Set with LRS Chamber). The disposable tubing set was primed with 0.9% sodium chloride plus 20 cc acid-citrate-dextrose formula A (Fenwal) in the inlet line before attachment to the horse.
The equipment, which is designed for use in humans, was adapted for the equine donors by selecting the largest body size parameters the machine allowed-a 7-foot-tall, 500-pound female. Preliminary blood work (platelet count and hematocrit values) from each horse was used to manually input baseline platelet count and total blood volume of the equine donor for calculation of a more appropriate infusion rate, pump rate, and inlet flow rate. The apheresis was completed after 1 L of platelet concentrate was collected in the collection bag. These procedures were carried out with the collaboration of a specialized apheresis technician from Emory University.
Venous access and drug administration
Before jugular catheter placement, the sites of venipuncture were clipped, prepared with 4% chlorhexidine and 70% isopropyl alcohol, and the skin was desensitized with a 1.5-mL subcutaneous bleb of 2% lidocaine (Hospira). Horses were never anesthetized for any portion of the procedure; however, if necessary, they were initially sedated with intravenous detomidine (Dormosedan; Zoetis) at 0.1 mg/kg before catheter placement. Once intravenous access was secured, horses were walked into a set of stocks and attached to an intravenous drip set through which 40 mcg/mL solution of detomidine in normal saline was administered at a starting rate of approximately 0.6 mcg/kg/min for the first 15 minutes and then adjusted to maintain a steady plain of sedation. Subsequently, an access line, which drew blood from the donor into the machine, was established through a 5.25-inch, 12-gauge catheter (MILA International) placed in the right jugular vein. A return line, which carried blood from the machine back to the donor, was established with a 5.25-inch, 14-gauge, extended use catheter (MILA International) placed in the left jugular vein. Horses were then restrained in stocks.
Blood sampling and physical examination
A physical examination was conducted at the start of plateletpheresis and every 30 minutes during the procedure to evaluate mentation, mucous membranes, temperature, pulse, respiratory rate, and blood pressure. Blood was collected through the access line before any sedation with the exception of individuals that required 0.1 mg/kg detomidine for catheterization. In these individuals, blood was drawn from the access line catheter placed after administration of 0.1 mg/kg of detomidine. Venous blood was placed in ethylenediaminetetraacetate, sodium citrate, and serum tubes for complete blood count (CBC), chemistry, and coagulation panels, respectively.
The access line catheter was maintained for continued sampling after the procedure. Blood was collected immediately after plateletpheresis and then at 8, 16, 24, and 48 hours later. A physical examination, as described above, with the exception of blood pressure, was conducted at the same time points as blood collection and at 36 hours after plateletpheresis.
Hematologic parameters
All CBCs using ethylenediaminetetraacetate-preserved blood samples were analyzed within 1 hour of collection using an automated hematology system (Heska CBCDiff). Within the same time frame, blood samples collected in sodium citrate and serum tubes were centrifuged and then stored at 2808C. Samples were submitted to the UGA Clinical Pathology Laboratory to measure prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and ionized calcium.
PL preparation and characterization
After plateletpheresis, lines to the collection bag were knotted and sealed with hemostatic forceps. The collection bag was then transported to the research laboratory within 1 hour, when the platelet concentrate was aliquoted into 50-mL conical tubes using sterile technique. A sample was also taken for a CBC to evaluate the platelet count as well as red blood cell and white blood cell contamination. The platelet concentrate was then stored at 2808C.
To produce the PL, the platelet concentrate was subjected to two freeze-thaw cycles to fracture the platelets and release cellular content, as described by Griffiths and coworkers. 25 The freeze-thaw cycles were followed by three separate centrifugation cycles, including a 60-minute spin (4800 3 g) at 48C and two 30-minute spins (4800 3 g) at room temperature. Subsequently, the product was filtered through a 40-lm Falcon cell strainer (Corning, Inc.) followed by a Stericup sterile vacuum filter unit with 0.45-lm cellulose acetate membrane (EMD Millipore) to remove cellular debris, including platelet membrane particles. At the end of the procedures described above, a 5-mL aliquot of PL was stored at 2808C and then submitted to the UGA Clinical Pathology
Laboratory for a CBC and fibrinogen analysis. The final PL product was stored at 2808C.
Bacterial and fungal culture
Two 10-mL samples were collected from each donor PL using sterile technique and placed into two Bactec media bottles (Becton Dickinson) according to the manufacturer's instructions. Samples were evaluated for aerobic, anaerobic, and fungal growth. The samples were assessed for the presence of microorganism every 24 hours up to 14 days. In addition, aerobic samples were plated on fungal media and observed for 30 days.
Growth factor analysis
The PL samples from each horse and pooled samples from all horses were analyzed using immunoassays (Quantikine Immunoassay; R&D Systems) for plateletderived growth factor-BB (PDGF-BB) and transforming growth factor-b1 (TGF-b1) immunoassay (VetSet) for vascular endothelial growth factor-A (VEGF-A) according to the manufacturer's instructions.
Statistical analysis
Normality of the data and equality of variances were assessed using Shapiro-Wilks and Levene's test, respectively. A one-way analysis of variance with repeated measurements was used to assess the effect of sampling time on hematologic and biochemical variables of the donors. When necessary based on the overall F test, multiple pairwise comparisons were performed using the TukeyKramer test. All analyses were performed using statistical software (Stata version 13.1; StataCorp LP), and p values less than 0.05 were considered significant.
RESULTS
Plateletpheresis procedure
All horses completed the procedure (1 L of platelet concentrate collected) in approximately 3 hours, and physical examination parameters remained within normal limits with the exception of temperature. Varying degrees of mild hypothermia were observed in all six horses after 30 to 120 minutes of apheresis with the lowest temperature recorded at 96.48F (35.78C) at the end of the procedure. The temperature of all horses returned to normal 4 hours after apheresis. The mean platelet count for the platelet concentrate was 357 6 177 3 10 3 /lL (Table 1 ). This was a 1.8-fold increase compared with the mean platelet count in whole blood. The spillover of white blood cells and red blood cells was minimal. Platelet concentrates contained from 0 to 0.6 3 10
Hematologic parameters
The mean platelet count in whole blood before plateletpheresis was 193 3 10 3 /lL. After plateletpheresis, there was a significant decrease in the mean platelet count to 138 3 10 3 /lL (p 5 0.005). The lowest postprocedure platelet count was 98 3 10 3 /lL. There was no significant statistical difference in mean platelet counts between any other time points (Fig. 1) . Individual donor platelet counts across sampling time points are outlined in Table 2 . Platelet counts recovered to match prepheresis levels 16 hours postprocedure for five of the six horses. One horse had a platelet count that remained below the prepheresis value for the 48-hour monitoring period. Seven days after the procedure, an additional blood sample was obtained from this horse and indicated that the platelet count remained below the prepheresis value and just below the normal reference interval. However, an extra sample taken 7 months after the procedure showed a platelet count equal to the prepheresis value.
Four of six horses were mildly anemic immediately after plateletpheresis, with red blood cell counts (range, 5.53-6.37 310 6 /lL) and hematocrits (range, 25.7-31.1%) slightly below the reference interval (range, 6.6-11 310 6 / lL and 30-44%). 26 No clinical signs of anemia, such as pale mucous membranes and tachycardia, were noted during or after the procedure. 27 Red blood cell counts and hematocrits were within the reference interval 8 hours after plateletpheresis for all six horses. No significant changes were noted in white blood cell values. However, lymphopenia was noted in all donors immediately after and up to 16 hours after plateletpheresis. Lymphocyte counts returned to normal or prepheresis values for four of six horses by 48 hours after the procedure. Five of six horses exhibited neutrophilia 24 hours after plateletpheresis, and four continued to have neutrophilia 48 hours after plateletpheresis.
Coagulation factors PT, aPTT, and fibrinogen all remained within normal limits over the 48-hour sampling period. A significant difference was noted in fibrinogen values before and after plateletpheresis compared with the 24-hour and 48-hour values, with higher values at the 24-hour and 48-hour time points (p 5 0.0001) (Fig. 2A) . No significant difference was observed between sample time points for PT or aPTT (Fig. 2B,C) .
No significant difference was observed between the sample time points for ionized calcium. Levels in three of the six horses dropped slightly below the reference interval immediately after plateletpheresis, with the lowest at 1.1 mmol/L (Fig. 2D) . Ionized calcium levels did not statistically correlate with the volume of anticoagulant infused to the donor. No signs of hypocalcemia were observed on physical examination in 4 hours after plateletpheresis, and all horses had ionized calcium levels within the reference interval 24 hours after the procedure.
PL characterization
Approximately 875 mL of PL was obtained from each liter of platelet concentrate. Cellular analysis via CBCs revealed only marginal cellular residue. The residual white blood cell count was minimal at 0.01 6 0.008 3 10 3 /lL, and the residual platelet numbers were 3.2 6 1.5 10 3 /lL. In addition, fibrinogen content was measured at 144 6 48 mg/dL in individual samples and at 177 mg/dL in pooled PL from all six individuals. Bacteriology and fungal tests were negative for all six individual PL samples.
Growth factor analysis
The mean concentrations of growth factors in the individual samples of PL were 7.3 6 1.8 ng/mL for TGF-b1, 3.6 6 2.2 ng/mL for PDGF-BB, and 11.2 6 16.0 ng/mL for VEGF-A. The pooled PL from all six horses had growth factor concentrations at 6.1 ng/mL for TGF-b1, 3.5 ng/mL for PDGF-BB, and 13.8 ng/mL for VEGF-A (Fig. 3) .
DISCUSSION
The results of this study indicate that standing, sedated horses can safely undergo plateletpheresis using a commercially available apheresis machine. The adaptation of this equipment, which is commonly used for apheresis in humans, to the horse was straightforward and resulted in the collection of a predictable volume of platelet concentrate, which was then processed to manufacture PL. In this study, we hypothesized that plateletpheresis was going to be safe and would not cause any ill effects in donor horses. During the course of the study, we did not observe any changes in physical examination parameters that could be attributed to the procedure itself. However, we did document various degrees of hypothermia that likely were secondary to sedation with detomidine, an a2-adrenergic agonist. A documented side effect of detomidine is depression of thermoregulatory responses by affecting a2-adrenergic receptors in the hypothalamus and decreasing prostaglandin E 2 production. This is a dose-dependent response, which can cause hypothermia at low doses and hyperthermia at high doses. [27] [28] [29] Our objectives were to assess several hematologic parameters before and after the procedure to determine the rate of platelet recovery and to document any variation in coagulation variables. The coagulation factors PT and aPTT were not significantly affected, and the lowest platelet count at 98 3 10 3 /lL was just below the reference interval (100 3 10 3 /lL). Therefore, no individual horse was at risk for increased bleeding tendencies. 27 Donor platelet counts immediately after plateletpheresis were lower than expected considering the relatively low platelet yield in the platelet concentrate. It has been demonstrated that detomidine causes splenic relaxation and elongation, which can lead to both platelet and red blood cell sequestration. 30 This may account for the lower than expected platelet and red blood cell counts immediately after the procedure as well as their quick recovery 8 hours later. A small but significant increase in fibrinogen observed at the 24-hour and 48-hour time points may indicate a mild inflammatory response. Abnormalities seen in white blood cell concentrations, namely, lymphocytes and granulocytes, may be attributed to inflammation induced by the procedure or corticosteroid-mediated stress due to a change in environment, increased handling, and stall confinement. Future work with equine apheresis should consider controlling for the excitability of equine donors and provide ample time for acclimation when donor transport precedes plateletpheresis.
Infusions of citrate-based anticoagulants during apheresis procedure are known to cause hypocalcemia in human and canine donors. 23 Citrate decreases available calcium levels by binding free calcium and rendering it inactive. 31 However, the protocol used in this study did not cause clinically significant hypocalcemia in equine donors. The measurement of total blood calcium levels includes ionized calcium (active form), protein-bound calcium, and calcium complexed to other molecules, such as citrate. Therefore, in this study, we measured ionized calcium to evaluate biologically active blood calcium levels. Ionized calcium levels in the equine donors dropped below the reference interval immediately after the procedure, but not to a point of concern, and returned to normal limits within 24 hours. Initial clinical signs of hypocalcemia, which include ataxia, muscle tremors, salivation, sweating, dysphagia, tachycardia, and hyperthermia, are difficult to monitor during the procedure, because they may appear similar to side effects of sedation with detomidine. 27, 28 Nevertheless, physical examination parameters obtained 4 hours after the procedure and after recovering from sedation indicated no clinical signs of hypocalcemia. It is suggested that horses undergoing plateletpheresis with the use of citrate-based anticoagulant should be monitored for clinical signs of hypocalcemia after the procedure. Previous studies in humans, dogs, and swine reported that the concentration of platelets in platelet concentrates derived from apheresis are usually 2.6 to 7 times higher than in whole blood. 23, [32] [33] [34] In this study, platelet concentrations in platelet concentrate ranged from 1 to 2.3 times higher than those in whole blood. Several factors may explain the lower platelet counts found in equine donors, including donor selection, species differences, and equipment limitations. The apheresis machine collection sensor is designed for human platelets in human plasma and is not calibrated for equine platelets or plasma. Equine platelets are smaller compared with human, canine, and porcine platelets, which are relatively similar in size (Table  3) . [35] [36] [37] Size variations are not isolated to platelets. Other blood cells, such as red blood cells, vary by species and may factor into the efficiency of platelet sorting during plateletpheresis (Table 3 ). In addition, equine plasma is more viscous and contains higher levels of pigments, such as bilirubin and carotene (Table 3) . [37] [38] [39] [40] Thus, species variation and smaller platelets in a more viscous and pigmented plasma may have reduced the efficiency of the apheresis machine to properly identify and collect equine platelets. The PL obtained from the collected platelet concentrate was evaluated for three growth factors: TGF-b1, PDGF-BB, and VEGF-A. The PDGF-BB and TGF-b1 concentrations were fairly consistent across the individual samples in this study, but large ranges were observed in VEGF-A concentrations (range, 0.6-30.9 ng/mL). The variability found in this study may be due to individual variability and/or assay sensitivity. For example, Giraldo and colleagues reported that female horses and horses less than 5 years old have significantly higher plasma concentrations of TGF-b1 and produce platelet products, such as platelet-rich plasma, with higher concentrations of PDGF-BB than males or horses older than 5 years. 41 Considering individual variation, pooling of PL would be beneficial for producing a more consistent PL. The growth factor concentrations in the equine PL obtained in this study are lower compared with those obtained with previously studied methods for equine PL. 5 However, the TGF-b1 concentration in equine PL is comparable to that of FBS, which was 6.2 ng/mL according to Doucet and coworkers. 4 Growth factor concentrations also were much higher than reported in a previous study of equine plasma. 41 The ideal growth factor concentrations for regenerative therapy and stem cell culture are unknown, and further research is warranted. The benefits of equine plateletpheresis include the collection of large volumes of platelet concentrate from standing and awake horses, which can then be used to produce PL. In addition, the process of producing PL from an apheresis platelet concentrate generally involves fewer steps than a protocol from whole blood and may decrease the likelihood of contamination. Although the optimal time frame between equine plateletpheresis donations has yet to be established, an individual can donate multiple times. The ability to pool and store PL for at least 1 year suggests the possibilities of standardizing PL for use in regenerative medicine. 33 In conclusion, this study determined that plateletpheresis is a safe method for collecting large volumes of platelet concentrate from the standing equine donor. The PL obtained from the platelet concentrate contained growth factors TGF-b1, PDGF-BB, and VEGF-A.
